Literature DB >> 2788028

Decreased natural killer (NK) activity in patients with myeloproliferative disorders.

P Froom1, E Aghai, A Kinarty, N Lahat.   

Abstract

Natural killer (NK) cell number and activity were measured in 26 patients with myeloproliferative disorders and the results were compared with 16 age-matched control patients. The percent of Leu-11b-positive cells was 11% +/- 3% in the patients, compared with 12% +/- 4% in the control patients. Ten of 26 patients, however, had NK activity lower than all of the control values at three different effector to target cell ratios (E:T) (P less than 0.005). The values of those patients with low unstimulated NK activity remained low despite stimulation with interleukin-2 (IL-2) or alpha-interferon (alpha-IFN), whereas the values of those patients with normal unstimulated activity responded to IL-2 and alpha-IFN like the control patients. Three of the ten patients with low NK activity had a history of malignant neoplasms. None of the 16 patients with normal NK activity had a history of malignant neoplasms (P less than 0.05). We conclude that patients with myeloproliferative disorders frequently have low endogenous NK cell activity in vitro. The dysfunction of the NK system appears to be intrinsic because the relative number of NK cells was similar to control values and the response to stimulation with IL-2 and alpha-IFN was suboptimal. There may be a relationship between low NK activity and the development of malignant disease in such patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788028     DOI: 10.1002/1097-0142(19890901)64:5<1038::aid-cncr2820640513>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Authors:  Marco Romano; Daria Sollazzo; Sara Trabanelli; Martina Barone; Nicola Polverelli; Margherita Perricone; Dorian Forte; Simona Luatti; Michele Cavo; Nicola Vianelli; Camilla Jandus; Francesca Palandri; Lucia Catani
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 2.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 3.  PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review.

Authors:  Jen-Chin Wang; Lishi Sun
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

4.  Daily intake of probiotics with high IFN-γ/IL-10 ratio increases the cytotoxicity of human natural killer cells: a personalized probiotic approach.

Authors:  Yu-Hsuan Ho; Yu-Chiu Lu; Hung-Cheng Chang; Shin-Yi Lee; Min-Fen Tsai; Yu-Ting Huang; Ting-Yuan Hsu
Journal:  J Immunol Res       Date:  2014-12-11       Impact factor: 4.818

5.  Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.

Authors:  Amanda Fernandes de Oliveira Costa; Leticia Olops Marani; Thiago Mantello Bianco; Adriana Queiroz Arantes; Izabela Aparecida Lopes; Diego Antonio Pereira-Martins; Leonardo Carvalho Palma; Priscila Santos Scheucher; Josiane Lilian Dos Santos Schiavinato; Larissa Sarri Binelli; Cleide Araújo Silva; Susumu S Kobayashi; João Agostinho Machado-Neto; Eduardo Magalhães Rego; Robert Samuel Welner; Lorena Lobo de Figueiredo-Pontes
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

6.  The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.

Authors:  Martina Barone; Lucia Catani; Francesca Ricci; Marco Romano; Dorian Forte; Giuseppe Auteri; Daniela Bartoletti; Emanuela Ottaviani; Pier Luigi Tazzari; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Oncoimmunology       Date:  2020-06-23       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.